Chimeric antigen receptor (CAR) T-cell therapy has been a game changer in the treatment of B-cell malignancies, although their manufacturing process is complex and needs lymphodepletion, thus limiting their use. Researchers from Capstan Therapeutics Inc. have recently published data regarding an in vivo engineering approach to generate CAR T cells using targeted lipid nanoparticles (LNPs) for mRNA delivery to specific T-cell populations for the treatment of cancer and B-cell-mediated autoimmune diseases.
Regulatory T cells (Tregs) maintain immune homeostasis by inhibiting excessive immune responses. Dysregulation of Tregs, characterized by reduced cell numbers or impaired suppressive function, is implicated in the pathogenesis of autoimmune diseases. Low-dose interleukin-2 (IL-2) therapy expands Tregs and enhances their suppressive capacity while minimizing the activation of T cells and natural killer (NK) cells.
The aberrant immune response against self-antigens occurring in autoimmune diseases involves dysregulation of members of intracellular signal transduction pathways such as interleukin-2-inducible T cell kinase (ITK) and Janus kinase (JAK). Aclaris Therapeutics Inc. has detailed the characterization of ATI-2138, a dual ITK/JAK3 covalent inhibitor.
Visterra Inc., a subsidiary of Otsuka Pharmaceutical Co. Ltd., reported positive top-line data from the ongoing Visionary phase III study of sibeprenlimab, an anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN).
Visterra Inc., a subsidiary of Otsuka Pharmaceutical Co. Ltd., reported positive top-line data from the ongoing Visionary phase III study of sibeprenlimab, an anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN).
The immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein VAV1 plays a key role in mediating T-cell receptor (TCR) and B-cell receptor (BCR) activity and signaling.
Females have a much greater risk of developing an autoimmune disease than males do. Eighty percent of autoimmune disease patients are female, and specific disorders can have an even more lopsided ratio – 90% of systemic lupus erythematosus (lupus) and almost 95% of Sjögren’s disease patients are female.
